NRx Says Data Positive From Expanded Access Protocol in Covid-19; Shares Up
June 15 2021 - 9:08AM
Dow Jones News
By Michael Dabaie
NRx Pharmaceuticals said data were positive from its Zyesami
expanded access protocol in Covid-19, sending shares 14% higher to
$20.50 premarket.
The expanded access protocol included 240 intensive care unit
patients suffering critical Covid-19 with respiratory failure who
had exhausted all approved therapies. The clinical stage
pharmaceutical company said that overall, patients receiving at
least one dose of Zyesami in addition to intensive care were alive
at 28 days.
This EAP provided an opportunity for regional hospitals to offer
Zyesami to its sickest patients, for whom no other options were
available, and who couldn't enroll in a study due to additional
risk factors. Enrollment in the EAP was offered to patients who
were ineligible for the Zyesami phase 2b/3 clinical trial, and who
had exhausted all approved therapies for Covid-19.
NRx said 56% of patients enrolled were already receiving
mechanical ventilation, and 44% were receiving non-invasive forms
of ventilation.
The company is providing the EAP data to the Food and Drug
Administration as "real world data", in support of the findings
from the Zyesami randomized controlled phase 2b/3 clinical
trial.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 15, 2021 09:04 ET (13:04 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
NRX Pharmaceuticals (NASDAQ:NRXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
NRX Pharmaceuticals (NASDAQ:NRXP)
Historical Stock Chart
From Apr 2023 to Apr 2024